FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter-Andreas Löschmann

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Activities & Behaviors

Motor Activity

Disorders

Secondary Parkinson Disease

Co-author Network

Publications

TOP 3
Klaus-Friedrich Bodmann; Wolfgang R Heizmann; Peter-Andreas Löschmann; Christian Petrik; Christof von Eiff; Christian Eckmann
Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
Peter-Andreas Löschmann; Carmen De Groote; Lance Smith; Ullrich Wüllner; Günther Fischer; John A Kemp; Peter Jenner; Thomas Klockgether
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Peter-Andreas Löschmann; Carmen De Groote; C Albrecht; MB Darstein; Colin Deransart; G Bernhard Landwehrmeyer; Carl Hermann Lücking; Thomas J Feuerstein
[3H]acetycholine release in rat striatal slices is not subject to dopamine heteroreceptor supersensitivity 30 months after 6-hydroxydopamine lesion of the substantia nigra.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter-Andreas Löschmann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Klaus-Friedrich Bodmann; Wolfgang R Heizmann; Peter-Andreas Löschmann; Christian Petrik; Christof von Eiff; Christian Eckmann
Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
Chemotherapy 2012;58(4):282-94.
2004: Peter-Andreas Löschmann; Carmen De Groote; Lance Smith; Ullrich Wüllner; Günther Fischer; John A Kemp; Peter Jenner; Thomas Klockgether
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Experimental neurology 2004;187(1):86-93.
2001: Peter-Andreas Löschmann; Carmen De Groote; C Albrecht; MB Darstein; Colin Deransart; G Bernhard Landwehrmeyer; Carl Hermann Lücking; Thomas J Feuerstein
[3H]acetycholine release in rat striatal slices is not subject to dopamine heteroreceptor supersensitivity 30 months after 6-hydroxydopamine lesion of the substantia nigra.
Naunyn-Schmiedeberg's archives of pharmacology 2001;363(4):414-21.
2000: Michael T Heneka; L Dumitrescu; Peter-Andreas Löschmann; Ullrich Wüllner; Thomas Klockgether
Temporal, regional, and cell-specific changes of iNOS expression after intrastriatal microinjection of interferon gamma and bacterial lipopolysaccharide.
Journal of chemical neuroanatomy 2000;18(4):167-79.
1999: Sybille Spieker; Peter-Andreas Löschmann; Thomas Klockgether
The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
Movement disorders : official journal of the Movement Disorder Society 1999;14(3):517-9.
1999: Ullrich Wüllner; Jan Seyfried; P Groscurth; S Beinroth; S Winter; Marc Gleichmann; Michael T Heneka; Peter-Andreas Löschmann; Jörg B Schulz; Michael Weller; Thomas Klockgether
Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function.
Brain research 1999;826(1):53-62.
1999: Ullrich Wüllner; J Kornhuber; M Weller; Jörg B Schulz; Peter-Andreas Löschmann; Peter Riederer; Thomas Klockgether
Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note.
Acta neuropathologica 1999;97(4):408-12.
1998: Karsten Schepelmann; Markus M Schugens; Peter-Andreas Löschmann; Thomas Klockgether; Johannes Dichgans
The non-competitive N-methyl-D-aspartate-antagonist memantine does not affect segmental mono- and polysynaptic reflexes in man.
Neuroscience letters 1998;257(3):159-61.
1998: J Rieger; M Ständer; Peter-Andreas Löschmann; Michael T Heneka; Johannes Dichgans; Thomas Klockgether; Michael Weller
Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer.
Oncogene 1998;17(18):2323-32.
1998: Jörg B Schulz; Michael Weller; R T Matthews; Michael T Heneka; P Groscurth; J C Martinou; J Lommatzsch; R von Coelln; Ullrich Wüllner; Peter-Andreas Löschmann; M Flint Beal; Johannes Dichgans; Thomas Klockgether
Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia.
Cell death and differentiation 1998;5(10):847-57.
1998: M Ständer; Ulrike Naumann; L Dumitrescu; Michael T Heneka; Peter-Andreas Löschmann; E Gulbins; Johannes Dichgans; Michael Weller
Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo.
Gene therapy 1998;5(9):1187-94.
1998: Michael T Heneka; Peter-Andreas Löschmann; Marc Gleichmann; Michael Weller; Jörg B Schulz; Ullrich Wüllner; Thomas Klockgether
Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide.
Journal of neurochemistry 1998;71(1):88-94.
1997: Bernd Mühlbauer; Christoph H Gleiter; C Gies; Gerd Luippold; Peter-Andreas Löschmann
Renal response to infusion of dopamine precursors in anaesthetized rats.
Naunyn-Schmiedeberg's archives of pharmacology 1997;356(6):838-45.
1997: MB Darstein; Peter-Andreas Löschmann; Rainer Knörle; Thomas J Feuerstein
Strychnine-sensitive glycine receptors inducing [3H]-acetylcholine release in rat caudatoputamen: a new site of action of ethanol?
Naunyn-Schmiedeberg's archives of pharmacology 1997;356(6):738-45.
1997: Ullrich Wüllner; Michael Weller; P Groscurth; Peter-Andreas Löschmann; Jörg B Schulz; I Müller; Thomas Klockgether
Evidence for an active type of cell death with ultrastructural features distinct from apoptosis: the effects of 3-acetylpyridine neurotoxicity.
Neuroscience 1997;81(3):721-34.
1997: Jörg B Schulz; D Bremen; J C Reed; J Lommatzsch; S Takayama; Ullrich Wüllner; Peter-Andreas Löschmann; Thomas Klockgether; Michael Weller
Cooperative interception of neuronal apoptosis by BCL-2 and BAG-1 expression: prevention of caspase activation and reduced production of reactive oxygen species.
Journal of neurochemistry 1997;69(5):2075-86.
1997: Ralf Dringen; O Kranich; Peter-Andreas Löschmann; Bernd Hamprecht
Use of dipeptides for the synthesis of glutathione by astroglia-rich primary cultures.
Journal of neurochemistry 1997;69(2):868-74.
1997: Peter-Andreas Löschmann; Ullrich Wüllner; Michael T Heneka; Jörg B Schulz; M Kunow; H Wachtel; Thomas Klockgether
Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Synapse (New York, N.Y.) 1997;26(4):381-91.
1997: Markus M Schugens; R Egerter; Irene Daum; Karsten Schepelmann; Thomas Klockgether; Peter-Andreas Löschmann
The NMDA antagonist memantine impairs classical eyeblink conditioning in humans.
Neuroscience letters 1997;224(1):57-60.
1997: Michael Weller; Jörg B Schulz; Ullrich Wüllner; Peter-Andreas Löschmann; Thomas Klockgether; Johannes Dichgans
Developmental and genetic regulation of programmed neuronal death.
Journal of neural transmission. Supplementum 1997;50():115-23.
1997: Michael T Heneka; Peter-Andreas Löschmann; H Osswald
Polymerized hemoglobin restores cardiovascular and kidney function in endotoxin-induced shock in the rat.
The Journal of clinical investigation 1997;99(1):47-54.
1996: Thomas Klockgether; Ullrich Wüllner; Joachim P Steinbach; V Petersen; L Turski; Peter-Andreas Löschmann
Effects of the antiparkinsonian drug budipine on central neurotransmitter systems.
European journal of pharmacology 1996;301(1-3):67-73.
1996: F Eblen; Peter-Andreas Löschmann; Ullrich Wüllner; L Turski; Thomas Klockgether
Effects of 7-nitroindazole, NG-nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions.
European journal of pharmacology 1996;299(1-3):9-16.
1996: Ullrich Wüllner; Peter-Andreas Löschmann; Jörg B Schulz; A Schmid; Ralf Dringen; F Eblen; L Turski; Thomas Klockgether
Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones.
Neuroreport 1996;7(4):921-3.
1995: Ullrich Wüllner; Peter-Andreas Löschmann; M Weller; Thomas Klockgether
Apoptotic cell death in the cerebellum of mutant weaver and lurcher mice.
Neuroscience letters 1995;200(2):109-12.
1995: Peter-Andreas Löschmann; F Eblen; Ullrich Wüllner; H Wachtel; T Kockgether
Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease.
European journal of pharmacology 1995;284(1-2):129-34.
1995: Sybille Spieker; Peter-Andreas Löschmann; C Jentgens; A Boose; Thomas Klockgether; Johannes Dichgans
Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings.
Clinical neuropharmacology 1995;18(3):266-72.
1995: Norbert Sommer; Peter-Andreas Löschmann; G H Northoff; M Weller; A Steinbrecher; Joachim P Steinbach; R Lichtenfels; Richard Meyermann; A Riethmüller; A Fontana
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.
Nature medicine 1995;1(3):244-8.
1995: Peter-Andreas Löschmann; F Eblen; Ullrich Wüllner; Thomas Klockgether
NMDA-mediated toxicity to striatal neurons is not reversed by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase.
Journal of neural transmission. Supplementum 1995;46():87-95.
1994: Thomas Klockgether; Peter-Andreas Löschmann; Ullrich Wüllner
New medical and surgical treatments for Parkinson's disease.
Current opinion in neurology 1994;7(4):346-52.
1994: Peter-Andreas Löschmann; Klaus W Lange; H Wachtel; L Turski
MPTP-induced degeneration: interference with glutamatergic toxicity.
Journal of neural transmission. Supplementum 1994;43():133-43.
1993: Peter-Andreas Löschmann; Thomas Klockgether; Markus M Schugens
Combination therapy for PD.
Neurology 1993;43(12):2725; author reply 2726-7.
1993: Klaus W Lange; Peter-Andreas Löschmann; Emin Sofic; M Burg; R Horowski; Karl-Theodor Kalveram; H Wachtel; Peter Riederer
The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates.
Naunyn-Schmiedeberg's archives of pharmacology 1993;348(6):586-92.
1993: Thomas Klockgether; P Jacobsen; Peter-Andreas Löschmann; L Turski
The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist.
Journal of neural transmission. Parkinson's disease and dementia section 1993;5(2):101-6.
1992: Andreas Kupsch; Peter-Andreas Löschmann; H Sauer; G Arnold; P Renner; D Pufal; M Burg; H Wachtel; G ten Bruggencate; Wolfgang H Oertel
Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice.
Brain research 1992;592(1-2):74-83.
1992: H Wachtel; M Kunow; Peter-Andreas Löschmann
NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
Neuroscience letters 1992;142(2):179-82.
1992: Klaus W Lange; Peter-Andreas Löschmann; H Wachtel; R Horowski; P Jähnig; Peter Jenner; CD Marsden
Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.
European journal of pharmacology 1992;212(2-3):247-52.
1992: Peter-Andreas Löschmann; M Kunow; H Wachtel
Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
Journal of neural transmission. Supplementum 1992;38():55-64.
1992: Peter-Andreas Löschmann; Lance A Smith; Klaus W Lange; P Jähnig; Peter Jenner; CD Marsden
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.
Psychopharmacology 1992;109(1-2):49-56.
1992: Peter-Andreas Löschmann; R Horowski; H Wachtel
Bromerguride--an ergoline derivative with atypical neuroleptic properties.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():263A-264A.
1991: L Turski; K Bressler; K J Rettig; Peter-Andreas Löschmann; H Wachtel
Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.
Nature 1991;349(6308):414-8.
1991: Peter-Andreas Löschmann; Klaus W Lange; M Kunow; K J Rettig; P Jähnig; T Honoré; L Turski; H Wachtel; Peter Jenner; CD Marsden
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Journal of neural transmission. Parkinson's disease and dementia section 1991;3(3):203-13.
1991: Peter-Andreas Löschmann; Lance A Smith; Klaus W Lange; P Jaehnig; Peter Jenner; CD Marsden
Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets.
Psychopharmacology 1991;105(3):303-9.
1990: L Turski; J S Andrews; Peter-Andreas Löschmann; K Bressler; Z A Bortolotto; L S Calderazzo-Filho; Esper A. Cavalheiro
Substantia nigra regulates action of antiepileptic drugs.
Brain research 1990;520(1-2):232-9.
1989: Peter-Andreas Löschmann; P N Chong; M Nomoto; P G Tepper; A S Horn; Peter Jenner; CD Marsden
Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437.
European journal of pharmacology 1989;166(3):373-80.
1988: H Wachtel; Peter-Andreas Löschmann; P Pietzuch
Absence of anticholinergic activity of rolipram, an antidepressant with a novel mechanism of action, in three different animal models in vivo.
Pharmacopsychiatry 1988;21(5):218-21.
1988: H Wachtel; K J Rettig; Peter-Andreas Löschmann
Effect of chronic subcutaneous minipump infusion of lisuride upon locomotor activity of rats.
Journal of neural transmission. Supplementum 1988;27():177-83.
1987: H Wachtel; Peter-Andreas Löschmann; H H Schneider; K J Rettig
Effects of forskolin on spontaneous behavior, rectal temperature and brain cAMP levels of rats: interaction with rolipram.
Neuroscience letters 1987;76(2):191-6.
1986: H Wachtel; Peter-Andreas Löschmann
Effects of forskolin and cyclic nucleotides in animal models predictive of antidepressant activity: interactions with rolipram.
Psychopharmacology 1986;90(4):430-5.